These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 32339438)
1. High-risk and intermediate-high-risk results from the ThyroSeq v2 and v3 thyroid genomic classifier are associated with neoplasia: Independent performance assessment at an academic institution. Jug R; Foo WC; Jones C; Ahmadi S; Jiang XS Cancer Cytopathol; 2020 Aug; 128(8):563-569. PubMed ID: 32339438 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytology. Valderrabano P; Khazai L; Leon ME; Thompson ZJ; Ma Z; Chung CH; Hallanger-Johnson JE; Otto KJ; Rogers KD; Centeno BA; McIver B Endocr Relat Cancer; 2017 Mar; 24(3):127-136. PubMed ID: 28104680 [TBL] [Abstract][Full Text] [Related]
3. Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel. Jug RC; Datto MB; Jiang XS Cancer Cytopathol; 2018 Jul; 126(7):471-480. PubMed ID: 29637728 [TBL] [Abstract][Full Text] [Related]
4. Thyroseq v3, Afirma GSC, and microRNA Panels Versus Previous Molecular Tests in the Preoperative Diagnosis of Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis. Silaghi CA; Lozovanu V; Georgescu CE; Georgescu RD; Susman S; Năsui BA; Dobrean A; Silaghi H Front Endocrinol (Lausanne); 2021; 12():649522. PubMed ID: 34054725 [TBL] [Abstract][Full Text] [Related]
9. Young Investigator Challenge: Molecular testing in noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Jiang XS; Harrison GP; Datto MB Cancer Cytopathol; 2016 Dec; 124(12):893-900. PubMed ID: 27893191 [TBL] [Abstract][Full Text] [Related]
10. Benign call rate and molecular test result distribution of ThyroSeq v3. Ohori NP; Landau MS; Carty SE; Yip L; LeBeau SO; Manroa P; Seethala RR; Schoedel KE; Nikiforova MN; Nikiforov YE Cancer Cytopathol; 2019 Mar; 127(3):161-168. PubMed ID: 30561907 [TBL] [Abstract][Full Text] [Related]
11. Impact of a genomic classifier on indeterminate thyroid nodules: an institutional experience. Abdelhakam DA; Mojica RE; Huenerberg KA; Nassar A J Am Soc Cytopathol; 2021; 10(2):155-163. PubMed ID: 33067175 [TBL] [Abstract][Full Text] [Related]
12. Clinical performance of a next-generation sequencing assay (ThyroSeq v2) in the evaluation of indeterminate thyroid nodules. Taye A; Gurciullo D; Miles BA; Gupta A; Owen RP; Inabnet WB; Beyda JN; Marti JL Surgery; 2018 Jan; 163(1):97-103. PubMed ID: 29154079 [TBL] [Abstract][Full Text] [Related]
13. Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules. Gortakowski M; Feghali K; Osakwe I Thyroid; 2021 Sep; 31(9):1376-1382. PubMed ID: 33764195 [No Abstract] [Full Text] [Related]
14. The role of ThyroSeq V3 testing in the management of patients with indeterminate thyroid nodules on fine needle aspiration. Selvaggi SM Diagn Cytopathol; 2021 Jul; 49(7):838-841. PubMed ID: 33864719 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of 167 Gene Expression Classifier (GEC) and ThyroSeq v2 Diagnostic Accuracy in the Preoperative Assessment of Indeterminate Thyroid Nodules: Bivariate/HROC Meta-analysis. Borowczyk M; Szczepanek-Parulska E; Olejarz M; Więckowska B; Verburg FA; Dębicki S; Budny B; Janicka-Jedyńska M; Ziemnicka K; Ruchała M Endocr Pathol; 2019 Mar; 30(1):8-15. PubMed ID: 30591992 [TBL] [Abstract][Full Text] [Related]
16. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice. Witt RL Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717 [TBL] [Abstract][Full Text] [Related]